NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.